Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Enliven Therapeutics, Inc. - Common Stock (NQ: ELVN ) 23.00 +0.10 (+0.44%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Enliven Therapeutics, Inc. - Common Stock ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q2 2024 August 13, 2024 ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024 May 14, 2024 ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program April 11, 2024 Enliven Therapeutics' Phase 1 trial results for ELVN-001 in chronic myeloid leukemia (CML) patients. Explore the promising safety and efficacy data. Via Benzinga Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session April 11, 2024 Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. Via Benzinga Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday April 11, 2024 U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session. Via Benzinga Topics Stocks Exposures US Equities Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says April 09, 2024 Mizuho Securities initiates coverage on Enliven Therapeutics. Expectations high for late 2024 Phase 1 results. Enliven poised to revolutionize CML treatment, addressing current TKI limitations. Mizuho... Via Benzinga Wall Street Mixed As Tech Stocks Fall, Fed Meeting Begins March 19, 2024 Stocks are scattered midday Tuesday, as investors digest the semiconductor sector's pullback that's being led by the shares of Nvidia. Via Talk Markets Topics Economy Exposures Interest Rates 12 Health Care Stocks Moving In Tuesday's Intraday Session March 19, 2024 Via Benzinga Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session March 19, 2024 Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results. Via Benzinga National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday March 19, 2024 U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday. Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Tuesday's Pre-Market Session March 19, 2024 Via Benzinga ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023 March 14, 2024 ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace 12 Health Care Stocks Moving In Monday's After-Market Session February 26, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session January 16, 2024 Via Benzinga 7 A-Rated Biotech Stocks for Your August Buy List August 17, 2023 Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge. Via InvestorPlace Bears Reload On Mobileye After Sharp Gains In Stock Price May 28, 2023 Short interest on Mobileye Global fell from 23.9% to 21.2% in the week following the company’s Q1 results and FY23 guidance cut on April 27. However, Mobileye shares are up 31% from those lows over the... Via Talk Markets Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2023 March 29, 2023 Via Benzinga 7 Biotech Stocks Sitting in the Sweet Spot March 24, 2023 Biotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable. Via InvestorPlace Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023 March 03, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.